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Abstract
Purpose: To examine the association between statin medication use and sepsis risk after percutaneous
nephrolithotomy (PCNL).
Materials and Methods: Using medical claims data, we identified working-age adults with urinary stone disease
who were treated with PCNL. Among this cohort, we determined which patients had a prescription fill for a
statin agent that encompassed their surgery date. We then fitted logistic regression models to examine for
differences in rates of postoperative sepsis between statin users and nonusers. In addition, we evaluated the
frequency of nonfebrile urinary tract infections (UTIs) and intensive care unit (ICU) services utilization and
hospital length of stay (LOS) as a function of statin use.
Results: During the study period, at total of 2046 patients underwent PCNL, 382 (18.7%) of whom had a
prescription fill for a statin agent preceding their surgery. The overall rate of sepsis in this population was 3.8%.
After adjusting for patient health status and sociodemographic factors, the rate of postoperative sepsis was
comparable between statin users and nonusers (5.3% vs 3.5%, respectively; P= 0.105). In addition, UTI and
ICU utilization rates did not relate to statin use (P > 0.05 for all associations). Adjusted hospital LOS was
shorter among statin users, but the difference was clinically trivial (3.6 vs 4.1 days; P= 0.007).
Conclusions: Statin use is not associated with reductions in postoperative sepsis, nonfebrile UTIs, ICU utili-
zation, or hospital LOS after PCNL. To increase the safety of PCNL, urologists will have to consider other
processes of care (e.g., clinical care pathways).
Introduction
W ith reported stone-free rates ranging from 76%to 85%, percutaneous nephrolithotomy (PCNL) is
considered the treatment of choice for patients with large
renal calculi.1 Despite technologic advances that have in-
creased the safety of the procedure, PCNL is still associated
with measurable morbidity including postoperative sepsis, the
consequences of which can be catastrophic.2,3 Rates of sepsis
after PCNL are reported as high as 8%, which is 20 times higher
than other endourologic procedures.4–6 As such, the investiga-
tion of adjunctive therapies that may reduce the risk of sepsis
after PCNL is warranted. Statins may be one such therapy.
Emerging data suggest that the benefits of statins extend
beyond their lipid-lowering effects. Specifically, empiric work
shows that these medications exhibit both anti-inflammatory
and antioxidant properties, as well.7–9 Statins have been shown
to blunt the first step in the activation of the cellular cascade
of the immune system in reaction to microbial infection,
thereby lowering levels of cytokines, tumor necrosis factor,
and C-reactive protein—drivers of the sepsis response.10,11
To the extent that these properties can be leveraged to
modulate the systemic immune response, statin use may have
a role in the prevention of postoperative sepsis.12 Among
different populations, statin use has been shown to be asso-
ciated with lower rates of other types of infections, including
respiratory, blood, and urinary infections.13–16 No study yet,
however, has examined the infectious prophylaxis role of
statin in patients undergoing PCNL.
To address this knowledge gap, we conducted an obser-
vational study using medical claims from working-age
adults. After identifying patients with nephrolithiasis who
were treated with PCNL, we determined those who were
prescribed a statin medication preoperatively. We then
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estimated the risk of postoperative sepsis, comparing rates
between statin users and nonusers. Findings from our analysis
serve to inform urologists who manage urinary stone disease
on the utility of statin prophylaxis among PCNL patients.
Materials and Methods
Data source
For our study, we used Truven Health’s MarketScan
Commercial Claims and Encounters Database (2002–2006).
This database captures the healthcare utilization of an esti-
mated 5.6 million working-age adults and their dependents
with employer-sponsored benefit plans. Containedwithin these
data are all inpatient and outpatient claims submitted on a
beneficiary’s behalf, including detailed prescription drug in-
formation,whichwas important, given our interest in statinuse.
Study population
Through a previously described algorithm, we used
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9) diagnosis codes to identify
adults 18 to 64 years of age with one or more claims for
urinary stone disease.17,18 We then used relevant Current
Procedural Terminology codes to identify the subset of pa-
tients who underwent PCNL at some point during the study
interval. For study inclusion, we required that persons have
continuous enrollment in a benefit plan for a minimum of 120
days before and 30 days after the index date for their surgical
procedure. We excluded those enrolled in benefit plans from
which Truven Health did not receive prescription drug claims
in the 30 days before the procedure.
Exposure
We then used National Drug codes for 32 proprietary
and generic statin medications to distinguish between pa-
tients prescribed statin therapy before PCNL and those
who were not.19 We tracked statin use based on prescrip-
tion fill dates and the number of days supplied. A patient
was considered a statin user if he or she had a prescription
fill for a statin agent, where the days supplied encompassed
the procedure date and the 2 weeks before it. We chose a
2-week period because the anti-inflammatory of statins
have been observed within 2 weeks of treatment.20 For our
primary analysis, patients who stopped their statin more
than 90 days before the surgical procedure were classified
as nonusers. Patients who were taking statins at some point
between 90 days and 14 days of the index date were ex-
cluded from the study cohort because of possible residual
effects of statin therapy.
Outcomes
Our primary outcome of interest for this study was the
occurrence of sepsis after PCNL. We defined sepsis events
using an ICD-9 code-based algorithm. Within the 30-day
period after the procedure date, we said that a sepsis event
occurred if a patient had a claim filed on his behalf with one
or more of the following ICD-9 codes: 020.0x (septicemic),
038.xx (septicemia and its subtypes), 785.52 (septic shock),
790.7x (bacteremia), 995.91 (sepsis), 995.92 (severe sepsis),
and 780.6 (fever of unknown origin).
In addition to the occurrence of sepsis, we measured a
variety of secondary outcomes, including the occurrence of a
nonfebrile urinary tract infection (UTI), the use of intensive
care unit (ICU) services postoperatively, and hospital length
of stay (LOS). UTIs were identified in the 30-day period after
the surgery date using a previously described ICD-9 code-
based algorithm.21 Hospital LOS was defined using patient
admission and discharge status. ICU services use was de-
termined through standard revenue codes from the facility
claims filed within the 30-day surgical episode.
Statistical analysis
For our initial analytic step, we used t tests and chi-square
tests, where appropriate, to compare statin users and nonusers
across a variety of sociodemographic and clinical factors.
Specifically, we made comparisons based on patient age, sex,
surgery setting (inpatient vs outpatient), employee classifi-
cation (salaried vs nonsalaried), employment status (full- vs
part-time), benefit plan type (comprehensive, preferred pro-
vider organization, health maintenance organization, point-
of-service, or other noncapitated plan), residence within a
metropolitan statistical area, and geographic region of resi-
dence based on the United States Census regions (Northeast,
Midwest, South, or West).
Because a patient’s baseline health may contribute to his or
her sepsis risk, we assessed comorbidity using a modification
of the Charlson index.22 In addition, we identified all the
patients who had a medical claim filed for sepsis or a non-
febrile UTI within the 90-day window before the surgery date
using the ICD-9 codes mentioned above. Further, we deter-
mined those patients who were prescribed antimicrobial
therapy within 5 days of their procedure (but not including
the day of the procedure, which reflects standard antibiotic
prophylaxis).
After adjusting for the patient factors described above, we
then used multiple logistic regression to evaluate the asso-
ciation between statin use and the occurrence of postopera-
tive sepsis. We fitted similar models to assess the relationship
between statin use and UTI and ICU utilization rates. Finally,
we used multivariable Poisson regression to evaluate the
relationship between hospital LOS and the use of statin
therapy. We conducted all analyses using SAS (version 9.3)
statistical software. All tests were two-tailed with the prob-
ability of type I error at 0.05. Our Institutional Review Board
deemed this study to be exempt from its oversight.
Results
In total, we identified 2046 patients who met our inclusion
criteria. Among these patients, 382 (18.7%) were statin users.
When compared with nonusers, patients on statin therapy
were more likely to be older (P < 0.001) and men (P < 0.001)
(Table 1). With regard to socioeconomic status, statin users
were more likely to have full-time employment (P< 0.001),
be salaried (P = 0.005), and have amore generous benefit plan
(P< 0.005). They were also more likely to reside in the
Midwest and Northeast (P < 0.005). Perhaps more important,
a greater proportion of statin users had higher levels of co-
morbid illness and preoperative sepsis and UTI than nonusers
(P< 0.001).
Postoperative sepsis was uncommon in our cohort, oc-
curring in only 78 (3.8%) of patients. In 10% of these patients,
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sepsis was severe enough to warrant ICU admission, but no
deaths occurred in our cohort. More than 40% of sepsis events
occurred in the first 3 days after PCNL (Fig. 1). Only 13% of
patients with sepsis had a drainage tube (either a ureteral stent
or nephrostomy tube) inserted before the procedure. Patient
factors that were independently associated with the odds of
sepsis included the level of comorbid illness and whether or
not the procedure was performed on an outpatient or inpatient
basis (Table 2). On multivariable analysis, the occurrence of
an uncomplicated UTI or sepsis before surgery increased the
odds of postoperative sepsis by 71% (odds ratio [OR], 1.71;
95% confidence interval [CI], 1.06 to 2.76; P= 0.028).
Statin use, however, was not associated with any protective
effect against postoperative sepsis (OR, 1.61; 95%CI, 0.91 to
2.86; P= 0.105). As shown in Figure 2, statin users had ad-
justed rates of postoperative sepsis comparable to those of
nonusers (5.3% vs 3.5%, respectively; P= 0.105). In addition,
UTI and ICU utilization rates also did not differ between
statin users and nonusers (P= 0.113 and P = 0.666, respec-
tively). Although the mean of hospital LOS was shorter in
favor of statin users, this difference was trivial clinically (3.6
vs 4.1 days; P = 0.007).
Discussion
We found that the use of a statin medication was not as-
sociated with reduced rates of sepsis after PCNL. UTI and
ICU utilization rates also did not vary by statins use. While
this class of medications may have other salutary effects on
patient health, our collective findings do not support the use
of statin medications for sepsis prophylaxis among PCNL
patients.
One explanation for the lack of effect is because of in-
sufficient statistical power. Therefore, we performed a post
hoc power calculation to determine the minimum detectable
effect size in our study. With 2046 patients in our cohort (382
statin users) and a 5% type I error, we had 80% power to
Table 1. Comparisons Between Patients
Who Received Statin Therapy at the Time
of Percutaneous Nephrolithotomy
and Those Who Did Not
Statin use
Patient characteristic Yes No P value
No. of patients (%) 382 (18.7) 1664 (81.3)
Patient age, mean (SD) 55.6 (7.2) 47.6 (10.9) < 0.001
% Male 63.1 46.3 < 0.001
% Inpatient setting
procedure
63.9 68.3 0.098
% Benefit plan type < 0.001
Comprehensive 20.4 10.9
PPO 0.0 0.7
HMO 11.5 17.7
POS 9.7 11.9
Other noncapitated 58.4 58.7
% Salaried 22.3 16.2 0.005
% Full-time
employment
54.3 41.6 < 0.001
% Urban 75.7 77.6 0.403
% Charlson score: < 0.001
0 59.7 78.6
1 28.3 13.4
2 6.8 5.1
‡ 3 5.2 2.9
% Region of residence: < 0.001
Northeast 9.4 9.0
Midwest 35.6 26.3
South 45.6 48.9
West 8.6 15.3
Unknown 0.8 0.5
% Preoperative
antibiotic use
5.2 4.3 0.440
% Preoperative sepsis
or UTIs
69.6 60.3 0.001
% Preoperative use of
drainage tube
5.8 8.5 0.077
SD= standard deviation; PPO = preferred provider organization;
HMO = health maintenance organization; POS= point of service;
UTI = urinary tract infection.
FIG. 1. The interval between surgery and a sepsis
diagnosis.
Table 2. Multiple Logistic Regression Results
for Postpercutaneous Nephrolithotomy Sepsis
Patient characteristic OR 95% CI P value
Statin user
(nonusers= referent)
1.61 0.91 to 2.86 0.105
Female (male = referent) 1.15 0.70 to 1.87 0.586
Age 0.98 0.96 to 1.01 0.108
Inpatient setting
(outpatient = referent)
2.31 1.27 to 4.17 0.006
Charlson score
(‡3= referent)
0 0.38 0.14 to 1.0 0.013
1 0.74 0.26 to 2.11 0.370
2 0.99 0.31 to 3.21 0.260
Preoperative antibiotic use
(no antibiotics = referent)
0.85 0.29 to 2.42 0.769
Preoperative sepsis/UTI
(no preoperative sepsis
events/UTIs = referent)
1.71 1.06 to 2.76 0.028
Preoperative drainage tube
(no drainage tube = referent)
1.77 0.87 to 3.58 0.115
OR= odds ratio; CI = confidence interval.
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detect a 50% reduction in rate of sepsis between our treatment
and comparison groups. We observed, however, in both un-
adjusted and adjusted models, a higher rate of sepsis in our
statin user group. Therefore, we are not worried about in-
sufficient power to detect a clinically meaningful reduction in
sepsis rate.
Our study is not the first one to call into question the statin
utility for decreasing the infectious complications in medical
or surgical patients, however.23–25 In a recent meta-analysis,
pooled data from 11 trials reporting on the incidence of in-
fection among statin users found that statin use had no effect
on infection risk.26 Moreover, among patients who under-
went cardiac surgery, Trezzi and associates27 found no sig-
nificant difference in the rate of postoperative infection in
patients who were receiving statins (4.3%) compared with
patients who were not receiving statins (3.8%).
Data from our study highlighted some patient-specific
factors that were associated with sepsis: The level of co-
morbidity, a history of previous sepsis or UTI, and the am-
bulatory status of the procedure. Clinicians could use this
information when counseling patients on their sepsis risk. We
did not find any statistically significant association between
sepsis and age, sex, preoperative antibiotic use, or insertion of
a drainage tube before the surgical procedure.
There are several limitations to our study. First, because of
the observational nature of our study, the potential for residual
confounding exists. Second, while we accounted for many
patient-level variables associated with sepsis as well as vali-
dated measures of comorbidities (the Charlson index), certain
factors, such as obesity, stone type, and procedure duration,
may impact a patient’s sepsis risk and are not measurable
using sources of administrative data. Third, our patient cohort
was limited to working-age adults with insurance. While this
population may limit the external validity of our results, it is
important to note that this subgroup represents the one most
commonly affected by urinary stone disease.28
Finally, one limitation of working with claims data is that
we knowwhether or not the patients filled the prescription but
do not know if the patient actually took the medication as
prescribed. It is possible that issues related to a patient’s
noncompliance with prescribed therapy could affect our re-
sults. That being said, drug information from MarketScan
database is widely used.29
Notwithstanding these limitations, our study has clinical
implications for the treatment of patients undergoing PCNL.
While statin therapy may not be beneficial, there are com-
pelling data on the utility of intraoperative renal pelvis urine
cultures and stone cultures for predicting postoperative sep-
sis.30 Given our findings, urologists who perform PCNL
would be better served by directing their attention to tests like
these, specifically for the patients with high comorbidities
and previous history of UTIs. Moreover, there may be a role
for clinical care pathways, which may aid in the early rec-
ognition and management of sepsis, thereby lowering its
associated morbidity and mortality.
Conclusions
Our study does not support the use of statins for decreasing
the risk of sepsis in patients undergoing PCNL. Urologists
who care for patients with urinary stone disease should focus
their attention on other processes of care to prevent sepsis in
this population.
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FIG. 2. Statin outcomes. (A) Post-
percutaneous nephrolithotomy
(PCNL) sepsis rate; (B) Post-PCNL
urinary tract infection (UTI).
(C) Length of stay for PCNL patients;
(D) Intensive care unit (ICU) care
usage post-PCNL.
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